Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming [CNBC]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: CNBC
Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition. In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug “ Rezdiffra ,” to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of per year before insurance and other rebates. So, why is this approval so important? First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatohepatitis, or NASH, who also have moderate-to-advanced liver scarring. Some specialists have started calling the condition metabolic dysfunction-associated steatohepatitis, or MASH , to avoid potentially stigmatizing language. MASH is a serious form of liver disease characterized by excess fat buildup and inflammation. It can l
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label [Seeking Alpha]Seeking Alpha
- Madrigal Statement on the Passing of Dr. Stephen HarrisonGlobeNewswire
- Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]Seeking Alpha